Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 (CEACAM6) Antibody (FITC)

Background

CEACAM6, also known as CD66c (Cluster of Differentiation 66c), is a member of the carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), which belong to the larger immunoglobulin superfamily (IgSF). CEACAM6 is a glycoprotein primarily involved in intercellular adhesion, immune response modulation, and tumor progression. It is expressed on the surface of various cell types, particularly epithelial cells, granulocytes, and certain cancer cells. CEACAM6, like other CEACAM family members, plays a key role in cellular interactions and communication. In addition to its normal physiological roles in cell adhesion, CEACAM6 is implicated in tumorigenesis, especially in cancers like colorectal, pancreatic, lung, and breast cancer. CEACAM6 is often overexpressed in these malignancies, contributing to tumor growth, metastasis, and resistance to apoptosis. Its expression in the immune system and epithelial cells also means it has important functions in immune modulation and maintaining the integrity of epithelial barriers.